Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatment

NDT Plus

Volumn 3, Issue 3, 2010, Pages 328-330

  Zumrutdal, Aysegul ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

chronic renal failure; end stage renal disease; erythropoietin; sickle cell anaemia

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; BLOOD TRANSFUSION; CLINICAL ARTICLE; DRUG DOSE INCREASE; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LETTER; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

EID: 77955935536     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfq011     Document Type: Letter

References (4)

1. Breen CP, Macdougall IC. Improvement of erythropoietin-resistant anaemia after renal transplantation in patients with homozygous sickle-cell disease. Nephrol Dial Transplant 1998; 13: 2949-2952
2. Tomson CRV, Edmunds ME, Chambers K et al. Effect of recombinant human erythropoietin on erythropoiesis in homozygous sickle-cell anaemia and renal failure. Nephrol Dial Transplant 1992; 7: 817-821
3. Scettler V, Wieland E. A case report of darbepoetin treatment in a patient with sickle cell disease and chronic renal failure undergoing regular hemodialysis procedures that induce a dose dependent extension of blood transfusion intervals. Ther Apher Dial 2009; 13: 80-82
4. Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sickle cell anaemia? Lancet 1998; 352: 566-567